Apollomics
在场
Apollomics 是一家在股票代码 APLM (US) 下上市的公司。
高管
查看带有其 11 名主要高管的组织结构图
Apollomics 搜索最多的简介
- Guo-liang Yu, Executive Director, Chairman and Chief Executive Off...
- Kenneth Carter, Independent Director
- Glenn Vraniak, Independent Director
高管在Apollomics变化
- Peony Yu, Chief Medical Officer, 将于 20248月 退休 (新闻发布的2024七月5号).
- Sanjeev Redkar, President and Director, 将于 20248月 退休 (新闻发布的2024七月5号).
- Robert Lin已作为Director加入公司 (新闻发布的2024五月9号).
创建提醒
跟踪 Apollomics 的高管变动
生物技术
Apollomics 拥有 2,330 家竞争者，其中包括 Eurofins (卢森堡)、Lonza (瑞士) 和 Biogen (美国(美洲))。
Popular M&A news in 生物技术
- Nuvig Therapeutics 刚刚宣布为 161 筹款数百万美元。 (公布2024十二月5号).
- March Biosciences 刚刚宣布为 28 筹款数百万美元。 (公布2024十二月3号).
- Lyell Immunopharma 已收购 ImmPACT Bio (公布2024十一月29号).
生物技术 行业的其他推荐联系人
消息
Apollomics 的最新新闻稿
- Apollomics Announces the First Approval of Vebreltinib for MET Exon 14 Skip Non-Small Cell Lung Cancer | Apollomics, Inc.
- Apollomics Announces Report of Activity of Vebreltinib in Glioblastoma Multiforme (GBM) with PTPRZ-MET Fusion | Apollomics, Inc.
- Apollomics Announces Efficacy of Vebreltinib in NSCLC Patients with MetEx14 Skipping Mutation Achieving an Overall Response Rate (ORR) of 75% | Apollomics, Inc.
- Apollomics Announces Two New Cohorts in Global Phase 2 SPARTA Study of Vebreltinib in Non-Small Cell Lung Cancer and Other Solid Tumors with MET Dysregulation | Apollomics, Inc.
- Apollomics Reports First Half 2023 Financial Results and Provides Corporate Update | Apollomics, Inc.
- Apollomics Announces Presentations of Vebreltinib Data at ESMO 2023 | Apollomics, Inc.
- Apollomics to Present at the H.C. Wainwright 25th Annual Global Investment Conference | Apollomics, Inc.
- Presentations | Apollomics, Inc.
- Apollomics, a Company Developing Novel Oncology Therapies to Address Difficult-to-Treat Cancers, Announces Closing of Business Combination and Listing on Nasdaq | Apollomics, Inc.
- Apollomics Co-Founder and President, Sanjeev Redkar, Ph.D., to Speak at 23rd Annual R. Bryan Miller Symposium | Apollomics, Inc.
- View more press releases Close
通过电子邮件
